Medication info
Rosaplus Tablets

Rosaplus Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Korea Pavis Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200607941 · Notified 2006.07.27 · Insurance code 621802080

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia even when their blood pressure is controlled at this dose: Treatment may be started with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or more. Administration to these patients is not recommended, as loop diuretics are preferable to thiazide drugs in patients with more severe renal impairment. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medicine cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dose adjustment.
Child dose
Children (under 18 years): As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Korea Pavis Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for hypertensive patients whose blood pressure is not sufficiently controlled with monotherapy. It effectively controls blood pressure, reduces the risk of cardiovascular complications, and helps improve overall blood pressure management.

How to take

Adult dose

○ Adults The usual dose of this medicine is one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia even when their blood pressure is controlled at this dose: Treatment may be started with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or more. Administration to these patients is not recommended, as loop diuretics are preferable to thiazide drugs in patients with more severe renal impairment. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medicine cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dose adjustment.

Child dose

Children (under 18 years): As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm or even death to the fetus, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to any of the ingredients, certain kidney and liver function disorders, or pregnant or potentially pregnant women should not take this medication. Caution is needed when using this medication for patients with low blood pressure, poor kidney function, electrolyte imbalances, or elderly patients, especially those with a history of skin cancer or photosensitivity. While taking this medication, blood pressure may drop too low, and dizziness or drowsiness may occur, so care should be taken when driving or operating machinery. Due to the hydrochlorothiazide component, electrolyte imbalances may occur, and regular blood tests should be conducted to check levels of potassium, sodium, etc. Extra caution should be taken in case of symptoms such as vomiting or diarrhea. This medication can cause dangerously elevated potassium levels in the blood if taken concurrently with potassium-sparing diuretics or potassium supplements; therefore, potassium supplements should not be taken without consulting a physician. Interactions may occur if this medication is taken with other antihypertensives, diuretics, or antidiabetic agents, so it should be taken according to a doctor's instructions. Adverse reactions may include dizziness, cough, rash, muscle pain, etc. If severe allergic reactions or symptoms of angioedema occur, medical personnel should be notified immediately. This medication has not been shown to be safe or effective for children and adolescents, so it should not be administered to them. This medication should be stored away from direct sunlight and kept out of the reach of children. It should not be transferred to another container but should be stored in its original container.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • generalized abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 127 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin peeling phenomenon
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • nerve irritability
  • panic disorder
  • sensory abnormality
  • peripheral neuropathy
  • sleep disorder
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • skin dryness
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • enuresis
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsion
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • restlessness
  • renal failure
  • renal impairment
  • interstitial nephritis
  • mucocutaneous syndrome
  • toxic epidermal necrolysis
  • temporary blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylaxis
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that blocks light and preferably kept at room temperature, between 1 to 30 degrees Celsius. Storing it this way will help maintain its effectiveness over time.

Appearance and packaging

Appearance

Yellow oval film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.